凯科特研究:一项国际e-Delphi研究在临床实践中使用内流性CORT类固醇治疗KEloid
Qi Yin1, Albert Wolkerstorfer2, Oren Lapid3,4,5
1Department of Dermatology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1100 DD, Amsterdam, The Netherlands. q.yin@amsterdamumc.nl.
American journal of clinical dermatology
|September 19, 2024
概括
对于 keloids 进行内溶性皮质类固醇 (ICA) 给药显示了实践的可变性. 这项研究在关键ICA方面达成共识,旨在标准化治疗并改善 keloid 患者的治疗结果.
科学领域:
- 皮肤病学 皮肤病学
- 整形外科 整形外科 整形外科
- 伤口愈合 治愈 伤口愈合
背景情况:
- 静脉内皮质类固醇 (ICA) 是对 keloids 的首要治疗方法.
- 目前的ICA临床实践存在显著的变异性,阻碍了治疗结果的比较.
研究的目的:
- 为了实现国际专家的共识,在内伤性皮质类固醇 (ICA) 管理,以治疗状体.
- 为医生制定以证据为基础的临床建议,用于管理 keloids.
主要方法:
- 一个由23名皮肤科医生和专门从事 keloid 治疗的整形外科医生组成的国际小组参加了会议.
- 进行了两轮在线e-Delphi调查,随后举行了共识会议.
- 共识被定义为至少75%的参与者同意的共识.
主要成果:
- 在治疗目标,适应症,首选的皮质类固醇 (氨酸胺40毫克/毫升),最大剂量 (80毫克/月),注射间隔 (4周),疼痛最小化,注射器/针头大小 (1毫升,25/27G),终点 (白化) 和技术 (避免皮下注射,多次通过固体化物) 方面达成了共识.
- 没有共识的领域包括特定的剂量,局部麻醉方法和注射地点.
结论:
- 这项e-Delphi研究为ICA提供了关键的临床建议,用于 keloid 管理.
- 实施这些基于共识的指导方针可以提高治疗统一性,并可能改善 keloid 治疗结果.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:19Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K